Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISION: Osimertinib plus Capivasertib in EGFR-mutant NSCLC with PIK3CA/AKT1/PTEN alterations after first-line Osimertinib
ChiCTR2600116135Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Shanxi Province
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib and capivasertib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Cancer Hospital of Shanxi Province. Primary endpoints: Part A: Number of dose-limiting toxicities (DLTs), Part A: Adverse events (AEs) and serious adverse events (SAEs) and 2 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
osimertinibcapivasertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600116135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116135.